In Vitro Oocyte Maturation With Autologous Exosomes in Women

NCT ID: NCT07249411

Last Updated: 2025-11-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-02
• Study Completion Date: 2025-01-31

Brief Summary

This study is a preliminary, prospective, randomized, controlled clinical trial designed to evaluate the safety and feasibility of supplementing in vitro maturation (IVM) media with autologous exosomes in women with diminished ovarian reserve undergoing assisted reproductive technology. The purpose of the study is to determine whether autologous exosomes can support the meiotic progression of immature metaphase I oocytes during a 24-36 hour culture period and to establish whether the intervention is safe, biologically feasible, and suitable for further clinical evaluation. Mature oocytes obtained after culture are fertilized using intracytoplasmic sperm injection, and resulting embryos are cryopreserved for future transfer in a subsequent phase of the research. No embryo transfer is performed during this preliminary phase.

Detailed Description

Women with diminished ovarian reserve frequently present a high proportion of immature oocytes after controlled ovarian stimulation. These immature oocytes cannot be fertilized and limit the number of mature oocytes available for assisted reproductive procedures. Oocyte maturation is regulated by a coordinated set of intracellular signaling pathways, intercellular communication with granulosa cells, and molecular mechanisms that maintain meiotic arrest and trigger meiotic resumption. Emerging scientific evidence indicates that extracellular vesicles, including autologous exosomes, may play a role in supporting oocyte maturation through the transfer of bioactive molecules.

This preliminary clinical study was designed to evaluate the safety and feasibility of using autologous exosomes as a supplement to conventional in vitro maturation (IVM) media. The study population includes women aged 38-46 years with documented diminished ovarian reserve who declined oocyte donation and who met predefined clinical, endocrine, and reproductive criteria. All participants provided written informed consent. The study was conducted in accordance with national regulations and international ethical principles for research involving human subjects.

Eligible participants undergo controlled ovarian stimulation using recombinant follicle-stimulating hormone, human menopausal gonadotropin, and an antagonist protocol, followed by human chorionic gonadotropin triggering and oocyte retrieval. Only metaphase I oocytes are included in the intervention portion of the study. After identification, metaphase I oocytes are randomly assigned to one of two groups using a simple computer-generated randomization method.

In the control group, oocytes are cultured in conventional in vitro maturation medium. In the experimental group, oocytes are cultured in the same medium supplemented with a standardized quantity of autologous exosomes isolated from each participant according to the study protocol. Culture duration ranges from 24 to 36 hours. After the culture period, oocytes reaching metaphase II are fertilized via intracytoplasmic sperm injection to standardize the fertilization procedure. Embryos developing after fertilization are cultured under standardized laboratory conditions, evaluated according to established morphological criteria, and cryopreserved for use in a future phase of the research. Embryo transfer is not performed during this preliminary phase.

The primary objective of the study is to assess whether autologous exosome supplementation is feasible and safe for use in IVM culture systems. Secondary objectives include documenting the procedures involved in oocyte handling, fertilization, and embryo cryopreservation to support future phases of the study. The study does not include analysis of results or clinical outcomes, as no outcomes are permitted to be reported in the Protocol Section of the ClinicalTrials.gov record. A subsequent phase of the research will evaluate implantation, clinical pregnancy, and live birth after transfer of cryopreserved embryos generated in this protocol.

Conditions

Diminished Ovarian Reserve

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes o

• Group I (Control): MI oocytes were cultured exclusively in conventional IVM medium (VITROLIFE®).
• Group II (Experimental): MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system

Group Type: ACTIVE_COMPARATOR

MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system

Intervention Type: OTHER

MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system

MI oocytes were cultured exclusively in conventional IVM medium (VITROLIFE®).

MI oocytes were cultured exclusively in conventional IVM medium (VITROLIFE®).

Group Type: ACTIVE_COMPARATOR

MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system

Intervention Type: OTHER

MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system

Interventions

MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system

MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Women with primary or secondary infertility associated with diminished ovarian reserve, defined by ultrasound findings and laboratory parameters (FSH > 10 mIU/mL and estradiol < 60 pg/mL).
• Serum anti-Müllerian hormone (AMH) concentration < 1 ng/mL.
• Antral follicle count < 3-6 follicles per ovary.
• Anatomical preservation of both ovaries.
• Body mass index (BMI) between 24.5 and 30 kg/m².
• Absence of active oncological pathologies or connective tissue diseases (collagenopathies).
• No history of clinically relevant hematological disorders.
• Adequate serum levels of vitamins essential for reproductive function, including vitamin D, B-complex, and vitamin C.
• Last live birth within ≤ 10 years prior to study initiation.
• Normal thyroid function (TSH and free thyroid hormones within range).
• Absence of antiphospholipid antibody syndrome.
• Male partner with semen parameters within normal limits, according to the World Health Organization (WHO) criteria, 2010 (5th edition) and 2021 (6th edition).
• Signed informed consent for participation in the study.

Exclusion Criteria

• • Patients without a diagnosis of infertility.

• Women without documented diminished ovarian reserve.
• Serum anti-Müllerian hormone (AMH) concentration > 1 ng/mL.
• Antral follicle count > 3-6 follicles per ovary.
• Absence of one or both ovaries.
• Body mass index (BMI) > 30 kg/m².
• Presence of active oncological pathologies or connective tissue diseases (collagenopathies).
• History of clinically relevant hematological disorders.
• Deficient or altered serum levels of vitamins essential for reproductive function (vitamin D, B-complex, and vitamin C).
• Last live birth > 10 years prior to study initiation.
• Altered thyroid function (TSH or free thyroid hormones out of range).
• History of antiphospholipid antibody syndrome.
• Male partner with abnormal semen parameters according to the World Health Organization (WHO) criteria, 2010 (5th edition) and 2021 (6th edition).
• Refusal to sign informed consent for study participation.

• Minimum Eligible Age: 38 Years
• Maximum Eligible Age: 48 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Biotech Fertility C.A.

OTHER

Sponsor Role: lead

Responsible Party

Carmen Navarro

Reproductive Endocrinologist Consultant of Reproductive Medicine and Laparoscopic Surgery

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Biotech Fertility C.A

Caracas, , Venezuela

Countries

Venezuela

References

Horner K, Livera G, Hinckley M, Trinh K, Storm D, Conti M. Rodent oocytes express an active adenylyl cyclase required for meiotic arrest. Dev Biol. 2003 Jun 15;258(2):385-96. doi: 10.1016/s0012-1606(03)00134-9.

Reference Type: BACKGROUND

PMID: 12798295 (View on PubMed)

Schultz RM, Montgomery RR, Belanoff JR. Regulation of mouse oocyte meiotic maturation: implication of a decrease in oocyte cAMP and protein dephosphorylation in commitment to resume meiosis. Dev Biol. 1983 Jun;97(2):264-73. doi: 10.1016/0012-1606(83)90085-4.

Reference Type: BACKGROUND

PMID: 6189752 (View on PubMed)

Mehlmann LM. Stops and starts in mammalian oocytes: recent advances in understanding the regulation of meiotic arrest and oocyte maturation. Reproduction. 2005 Dec;130(6):791-9. doi: 10.1530/rep.1.00793.

Reference Type: BACKGROUND

PMID: 16322539 (View on PubMed)

Chand AL, Legge M. Amino acid transport system L activity in developing mouse ovarian follicles. Hum Reprod. 2011 Nov;26(11):3102-8. doi: 10.1093/humrep/der298. Epub 2011 Sep 13.

Reference Type: BACKGROUND

PMID: 21914669 (View on PubMed)

Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development. 2000 Oct;127(19):4277-91. doi: 10.1242/dev.127.19.4277.

Reference Type: BACKGROUND

PMID: 10976058 (View on PubMed)

Kiyama R, Wada-Kiyama Y. Estrogenic endocrine disruptors: Molecular mechanisms of action. Environ Int. 2015 Oct;83:11-40. doi: 10.1016/j.envint.2015.05.012. Epub 2015 Jun 11.

Reference Type: BACKGROUND

PMID: 26073844 (View on PubMed)

Coticchio G, Dal Canto M, Mignini Renzini M, Guglielmo MC, Brambillasca F, Turchi D, Novara PV, Fadini R. Oocyte maturation: gamete-somatic cells interactions, meiotic resumption, cytoskeletal dynamics and cytoplasmic reorganization. Hum Reprod Update. 2015 Jul-Aug;21(4):427-54. doi: 10.1093/humupd/dmv011. Epub 2015 Mar 4.

Reference Type: BACKGROUND

PMID: 25744083 (View on PubMed)

Esbert M, Reig A, Ballestros A, Seli E. Oocyte maturation defect in women undergoing IVF: contributing factors and effects on mature sibling oocyte outcomes. J Assist Reprod Genet. 2025 Mar;42(3):773-780. doi: 10.1007/s10815-024-03353-w. Epub 2025 Jan 9.

Reference Type: BACKGROUND

PMID: 39786528 (View on PubMed)

Coticchio G, Cimadomo D, Rienzi L. The daunting goal to rescue oocytes collected immature in conventional ovarian stimulation cycles. Fertil Steril. 2025 May;123(5):747-748. doi: 10.1016/j.fertnstert.2025.02.026. Epub 2025 Feb 22.

Reference Type: BACKGROUND

PMID: 39993495 (View on PubMed)

Navarro C, Torrecillas Cabrera P, Teppa Garran A. Comparative analysis of the use of autologous exosomes and platelet-derived growth factors in women with premature ovarian insufficiency and infertility: A prospective, randomized, observational, analytical study. Regen Ther. 2025 Jun 30;30:309-320. doi: 10.1016/j.reth.2025.06.007. eCollection 2025 Dec.

Reference Type: BACKGROUND

PMID: 40678344 (View on PubMed)

Tornell J, Billig H, Hillensjo T. Resumption of rat oocyte meiosis is paralleled by a decrease in guanosine 3',5'-cyclic monophosphate (cGMP) and is inhibited by microinjection of cGMP. Acta Physiol Scand. 1990 Jul;139(3):511-7. doi: 10.1111/j.1748-1716.1990.tb08953.x.

Reference Type: BACKGROUND

PMID: 2173353 (View on PubMed)

Cho WK, Stern S, Biggers JD. Inhibitory effect of dibutyryl cAMP on mouse oocyte maturation in vitro. J Exp Zool. 1974 Mar;187(3):383-6. doi: 10.1002/jez.1401870307. No abstract available.

Reference Type: BACKGROUND

PMID: 4362350 (View on PubMed)

Dekel N, Beers WH. Development of the rat oocyte in vitro: inhibition and induction of maturation in the presence or absence of the cumulus oophorus. Dev Biol. 1980 Mar 15;75(2):247-54. doi: 10.1016/0012-1606(80)90160-8. No abstract available.

Reference Type: BACKGROUND

PMID: 6154623 (View on PubMed)

Hinckley M, Vaccari S, Horner K, Chen R, Conti M. The G-protein-coupled receptors GPR3 and GPR12 are involved in cAMP signaling and maintenance of meiotic arrest in rodent oocytes. Dev Biol. 2005 Nov 15;287(2):249-61. doi: 10.1016/j.ydbio.2005.08.019. Epub 2005 Oct 17.

Reference Type: BACKGROUND

PMID: 16229830 (View on PubMed)

Kovanci E, Rohozinski J, Simpson JL, Heard MJ, Bishop CE, Carson SA. Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril. 2007 Jan;87(1):143-6. doi: 10.1016/j.fertnstert.2006.05.079. Epub 2006 Dec 6.

Reference Type: BACKGROUND

PMID: 17156781 (View on PubMed)

Vaccari S, Horner K, Mehlmann LM, Conti M. Generation of mouse oocytes defective in cAMP synthesis and degradation: endogenous cyclic AMP is essential for meiotic arrest. Dev Biol. 2008 Apr 1;316(1):124-34. doi: 10.1016/j.ydbio.2008.01.018. Epub 2008 Jan 26.

Reference Type: BACKGROUND

PMID: 18280465 (View on PubMed)

Other Identifiers

Exosom2025-1

Identifier Type: -

Identifier Source: org_study_id